Search results
Results from the WOW.Com Content Network
Puma was founded in September 2010 by Alan Auerbach to identify and in-license compounds that were already in clinical development. [2] This was the same business plan Auerbach had followed at Cougar Biotechnology, which he founded in 2003, and through which he in-licensed abiraterone acetate from BTG plc. [2]
Puma Biotech (PBYI) delivered earnings and revenue surprises of 90.91% and 11.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.
Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ...
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ...
Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.